The Radium-select Study
Condition(s) studied
Investigational drug(s) / intervention(s)
68Ga-PSMA-PET/CT scan: 68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
Study summary
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis. Patients are eligible for this treatment when they have mCRPC and bone metastases; limited extraskeletal lesions (local prostate, lymph nodes \<3 cm) on conventional contrast enhanced CT (ceCT) were allowed in the registration trial(1). Previous research revealed that extraskeletal disease on ceCT and bone scans correlates with a poor response. Meanwhile, 68Ga-PSMA-PET/CT emerged as more sensitive imaging strategy that increases the detection of extraskeletal prostate cancer metastases. It is unclear whether these extraskeletal lesions harbour any predictive value in the treatment of mCRPC patients with Radium-223.
Eligibility
Primary outcome measure(s)
- Clinical progression free survival (cPFS) — Up to 28 weeks
The primary study endpoint will be clinical progression free survival (cPFS) in 30 patients with bone-only disease according to PSMA PET/CT.
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| NKI-AVL | Amsterdam | North Holland | Recruiting |
| Meander Medisch Centrum | Amersfoort | Utrecht | Recruiting |
| Sint Antonius ziekenhuis | Nieuwegein | Utrecht | Recruiting |
| Diakonessenhuis | Utrecht | Netherlands | Not Yet Recruiting |
| UMC | Utrecht | Netherlands | Recruiting |
More The Netherlands Cancer Institute trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06659926 on ClinicalTrials.gov ↗ ← All trials in the Netherlands